Websites selling compounded versions of GLP-1 drugs are not allowed to use the FDA-approved brand names of products like Ozempic, Wegovy and Zepbound
Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
EmblemHealth and ConnectiCare do not cover all GLP-1 drugs for off-label use such as weight loss
Therefore, Klinic prioritizes prescribing FDA-approved weight management drugs like Wegovy, Oral Wegovy, Zepbound, and Foundayo
A Phase 3 trial run by the VA Office of Research and Development began enrolling in 2026 with estimated completion in April 2028
These applications are strictly exploratory and are designed to improve understanding of muscle biology and regulatory networks rather than to define any therapeutic protocol